艰难梭菌疫苗临床试验的研究现状及挑战  

Status and challenge of vaccine research for Clostridiodes difficile in clinical trials

作　　者：陶薇 傅婷(综述) 洪艳(审校) TAO Wei;FU Ting;HONG Yan(School of Laboratory Medicine and School of Bioengineering,Hangzhou Medical College,Hangzhou 310013,Zhejiang Province,China)

机构地区：[1]杭州医学院检验医学院、生物工程学院,浙江杭州310013

出　　处：《中国生物制品学杂志》2023年第9期1138-1142,共5页Chinese Journal of Biologicals

基　　金：浙江省教育厅一般科研项目(Y202146042)。

摘　　要：艰难梭菌(Clostridiodes difficile,C.difficile)是全球最常见引起抗生素相关腹泻(antibiotic-associated diarrhea,ADD)的病因。近年来,随着具有高抗药性和高毒力菌株的出现,造成多次艰难梭菌感染全球流行。艰难梭菌感染发病率、复发率和死亡率在全球范围内呈上升趋势,为临床治疗带来极大挑战。致病性菌株主要产生两种同源性糖基化毒素A和B,会造成从腹泻到高致死的中毒型巨结肠等症状。鉴于艰难梭菌感染造成的恶性后果,疾病的预防仍然是值得探索的重要途径。目前尚无获得使用许可的艰难梭菌疫苗,因此本文对艰难梭菌疫苗临床试验的研究现状及面临的挑战作一综述。Clostridiodes difficile(C.difficile)is the most common causative agent of antibiotic-associated diarrhea(ADD)in the world.In recent years,with the emergence of highly resistant and virulent strains,the outbreaks of C.difficile infection have occurred around the world.The incidence,recurrence and mortality of C.difficile infection are on the rise worldwide,and bring great challenges to clinical treatment.Pathogenic strains mainly produce two homologous glycosylation toxins A and B,which can cause symptoms ranging from diarrhea to highly lethal toxic megacolon.In view of the malignant consequences caused by C.difficile infection,disease prevention is still an important way worth exploring.Until now there is no approved vaccine against C.difficile.Therefore,this review assessed the status and challenge of clinical trials of vaccine research for C.difficile.

关 键 词：艰难梭菌 抗生素相关腹泻 疫苗 内毒素 单克隆抗体 

分 类 号：R183.4[医药卫生—流行病学]